Skip to content
10-Q

Quarterly Report

CADENCE PHARMACEUTICALS INC

0001193125-13-199170

← back to feed
Filed
May 3, 2013 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2013 · Apr 30, 2013 85.8M sh
Capex Q1 2013 · Mar 31, 2013 $26K
Capex Q1 2013 · Mar 31, 2012 $446K
Operating Cash Flow Q1 2013 · Mar 31, 2013 −$12.51M
Operating Cash Flow Q1 2013 · Mar 31, 2012 −$18.25M
Long Term Debt Q1 2013 · Mar 31, 2013 $26.39M
Long Term Debt Q1 2013 · Dec 31, 2012 $28.82M
Short Term Debt Q1 2013 · Mar 31, 2013 $2.55M
Cash And Equivalents Q1 2013 · Mar 31, 2013 $60.5M
Cash And Equivalents Q1 2013 · Dec 31, 2012 $58.33M
Cash And Equivalents Q1 2013 · Mar 31, 2012 $86.06M
Cash And Equivalents Q1 2013 · Dec 31, 2011 $82.61M
Stockholders Equity Q1 2013 · Mar 31, 2013 $48.15M
Stockholders Equity Q1 2013 · Dec 31, 2012 $47.81M
Current Liabilities Q1 2013 · Mar 31, 2013 $20.89M
Current Liabilities Q1 2013 · Dec 31, 2012 $21M
Total Liabilities Q1 2013 · Mar 31, 2013 $47.51M
Total Liabilities Q1 2013 · Dec 31, 2012 $49.87M
Current Assets Q1 2013 · Mar 31, 2013 $81.91M
Current Assets Q1 2013 · Dec 31, 2012 $76.52M
Total Assets Q1 2013 · Mar 31, 2013 $95.66M
Total Assets Q1 2013 · Dec 31, 2012 $97.68M
Sga Expense Q1 2013 · Mar 31, 2013 $21.64M
Sga Expense Q1 2013 · Mar 31, 2012 $23.53M
Rd Expense Q1 2013 · Mar 31, 2013 $1.36M
Rd Expense Q1 2013 · Mar 31, 2012 $1.51M
Net Income Q1 2013 · Mar 31, 2013 −$1.36M
Net Income Q1 2013 · Mar 31, 2012 −$22.67M
Operating Income Q1 2013 · Mar 31, 2013 −$7.94M
Operating Income Q1 2013 · Mar 31, 2012 −$21.62M
Cost Of Revenue Q1 2013 · Mar 31, 2013 $8.17M
Cost Of Revenue Q1 2013 · Mar 31, 2012 $4.25M
Revenue Q1 2013 · Mar 31, 2013 $23.61M
Revenue Q1 2013 · Mar 31, 2012 $8M